TitleGeneral Biomarker Recommendations for Lymphoma.
Publication TypeJournal Article
Year of Publication2016
AuthorsRimsza, Lisa, Fedoriw Yuri, Staudt Louis M., Melnick Ari, Gascoyne Randy, Crump Michael, Baizer Lawrence, Fu Kai, Hsi Eric, Chan John W. C., McShane Lisa, Leonard John P., Kahl Brad S., Little Richard F., Friedberg Jonathan W., and Kostakoglu Lale
JournalJ Natl Cancer Inst
Volume108
Issue12
Date Published2016 Dec
ISSN1460-2105
KeywordsBiomarkers, Tumor, Clinical Trials as Topic, Congresses as Topic, DNA, Neoplasm, Humans, Image Interpretation, Computer-Assisted, Lymphoma, Positron Emission Tomography Computed Tomography, Prognosis, Research Design, RNA, Neoplasm, Specimen Handling
Abstract

<p>Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of these tumors are indolent. The ability to determine treatment needs at diagnosis remains problematic for some of the tumors, such as in follicular lymphomas. Major clinical advances will likely depend on precision oncology that will enable identification of specific disease entities, prognostic determination at diagnosis, and identification of precise therapeutic targets and essential pathways. However, refinement in diagnostic evaluation is an evolving science. The ability to determine prognosis at diagnosis is variable, and for many of the lymphoid malignancies prognosis can only be made after initial treatment. Clinical trials that aim to evaluate specific features of these diseases are required in order to advance clinical practice that meaningfully addresses this important public health challenge. Herein, we describe the process and general recommendation from the National Cancer Institute (NCI) clinical trials planning meeting in November 2014 to address clinical trial design and biomarker proposals in the context of NCI-supported lymphoma clinical trials in the National Clinical Trials Network.</p>

DOI10.1093/jnci/djw250
Alternate JournalJ Natl Cancer Inst
PubMed ID27986882
PubMed Central IDPMC6080362
Grant ListU10 CA180888 / CA / NCI NIH HHS / United States